Abstract | BACKGROUND: METHODS: We did a randomised, multicentre, open-label trial in the USA and Canada of HIV-negative people with drug-susceptible pulmonary tuberculosis who had completed 2 months of a 6-month treatment regimen. We randomly allocated patients directly observed treatment with either 600 mg rifapentine plus 900 mg isoniazid once a week or 600 mg rifampicin plus 900 mg isoniazid twice a week. Primary outcome was failure/relapse. Analysis was by intention to treat. FINDINGS: 1004 patients were enrolled (502 per treatment group). 928 successfully completed treatment, and 803 completed the 2-year 4-month study. Crude rates of failure/relapse were 46/502 (9.2%) in those on rifapentine once a week, and 28/502 (5.6%) in those given rifampicin twice a week (relative risk 1.64, 95% CI 1.04-2.58, p=0.04). By proportional hazards regression, five characteristics were independently associated with increased risk of failure/relapse: sputum culture positive at 2 months (hazard ratio 2.8, 95% CI 1.7-4.6); cavitation on chest radiography (3.0, 1.6-5.9); being underweight (3.0, 1.8-4.9); bilateral pulmonary involvement (1.8, 1.0-3.1); and being a non-Hispanic white person (1.8, 1.1-3.0). Adjustment for imbalances in 2-month culture and cavitation diminished the association of treatment group with outcome (1.34; 0.83-2.18; p=0.23). Of participants without cavitation, rates of failure/relapse were 6/210 (2.9%) in the once a week group and 6/241 (2.5%) in the twice a week group (relative risk 1.15; 95% CI 0.38-3.50; p=0.81). Rates of adverse events and death were similar in the two treatment groups. INTERPRETATION:
Rifapentine once a week is safe and effective for treatment of pulmonary tuberculosis in HIV-negative people without cavitation on chest radiography. Clinical, radiographic, and microbiological data help to identify patients with tuberculosis who are at increased risk of failure or relapse when treated with either regimen.
|
Authors | Debra Benator, Mondira Bhattacharya, Lorna Bozeman, William Burman, Antonino Cantazaro, Richard Chaisson, Fred Gordin, C Robert Horsburgh, James Horton, Awal Khan, Christopher Lahart, Beverly Metchock, Constance Pachucki, Llewellyn Stanton, Andrew Vernon, M Elsa Villarino, Yong Chen Wang, Marc Weiner, Stephen Weis, Tuberculosis Trials Consortium |
Journal | Lancet (London, England)
(Lancet)
Vol. 360
Issue 9332
Pg. 528-34
(Aug 17 2002)
ISSN: 0140-6736 [Print] England |
PMID | 12241657
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibiotics, Antitubercular
- Isoniazid
- Rifampin
- rifapentine
|
Topics |
- Antibiotics, Antitubercular
(administration & dosage)
- Drug Administration Schedule
- Drug Therapy, Combination
- Ethnicity
- Female
- Humans
- Isoniazid
(administration & dosage)
- Male
- Middle Aged
- Radiography, Thoracic
- Rifampin
(administration & dosage, analogs & derivatives)
- Sputum
(microbiology)
- Treatment Outcome
- Tuberculosis, Pulmonary
(diagnostic imaging, drug therapy, microbiology)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|